FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED) X15930 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 10/542872 DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING PRIORITY DATE CLAIMED PCT/US2004/000020 **DATE 21 Jan 2004** 25 Feb 2003 (21.01.04)(25.02.03)TITLE OF INVENTION: CRYSTALLINE NON-SOLVATED 1-(4-(2-PIPERIDINYLETHOXY)PHENOXY)-2-(4-METHANESULFONYLPHENYL)-6-HYDROXYNAPHTHALENE HYDROCHLORIDE APPLICANT(S) FOR DO/EO/US: REMICK David Michael Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is transmitted herewith (required only if not transmitted by the International Bureau). h. has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau). a. b. have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. c. d. have not been made and will not be made. 8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form. 11. A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 12. to 18. below concern document(s) or information included: 12. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. Assignment has been recorded at reel \_\_\_\_\_\_, frame 15. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. A Sequence Listing, 1.821 Statement, and diskette. 17. A power of attorney with 3.73(b) certificate. 18. Other items or information: Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for 60/450/233 filed 25 February 2003, and PCT/US2004/000020 filed 21 Jan 2004, which, claim the benefit, under 35 USC 119(e), of US provisional application

60/450,233 filed 25 February 2003.

## JC14 Rec'd PCT/PTO 20 JUL 2005

U.S. APPLICATION NO GENOVED-Sec 32 PR. 452					INTERNATIONAL APPLICATION NO PCT/US2004/000020		O. ATTORNEY'S DOCKET NUMBER X15930			
19.	x	The following	ng fees are submitted	d:			CALCULATIONS PTO USE			
	Ba	J sic National S	tage Fee =		\$ 300.00	\$ 300.00				
	National Stage Examination Fee = \$\frac{\$200.00}{\$1,000.00}\$ (a)									
Application Length Fee										
Total Length (excluding sequence listings)										
14 - 100 = 0 excess pages (b)										
No extra charge for first 100 pages. Must pay \$250 for each adtl 50 pages (or fraction thereof).							į			
ENTER APPROPRIATE AMOUNT (a + b) =							\$1	000.00	Γ	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months							\$	000.00		
from t			priority date (37 CFI			D.A.TIC		·		
CLAIMS NUMBER FILED 1 Total claims 6-20= 0			NUMBER EXTRA	RATE X \$50.00	\$		<u> </u>			
						X \$200.00				
MULTIPLE DEPENDENT CLAIM(S) (if applicable					e)	+ \$360.00	\$			
TOTAL OF ABOVE CALCULATIONS =										
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).							\$ 0			
SUBTOTAL =							\$1,0	00.00		
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$			
TOTAL NATIONAL FEE =							\$1,0	00.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).  \$40.00 per property +							\$			
TOTAL FEES ENCLOSED =							\$ 1.	00.00		
							,	Amount to be refunded	\$	
	-,,							charged	\$	
<ul> <li>a.</li></ul>										
	(37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.  SEND ALL CORRESPONDENCE TO:									
ELI LI PATEN P.O. BC	LLY A IT DIV DX 628 NAPOI	ND COMPAN ISION 8 LIS, INDIANA	NY	<u>L</u>	SIGNATURE Gilbert T. Voy			25885		
REGIST	Date 43,972 EGISTRATION NUMBER  317-276-2966 TELEPHONE NUMBER							PATENT TRADEMARK		

## IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicant(s): REMICK, David Michael

International Application No.: PCT/US2004/000020

Filed: 21 January 2004 (21.01.04)

Invention: CRYSTALLINE NON-SOLVATED 1-(4-(2-PIPERIDINYLETHOXY)PHENOXY)-2-(4-

METHANESULFONYLPHENYL)-6-HYDROXYNAPHTHALENE HYDROCHLORIDE

Lilly Reference:

X-15930

Earliest Priority Date: 25 February 2003 (25.02.03)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO Mail Stop PCT Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number:

Date of Deposit:

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.

PTO/SB/96 (8-96) (MODIFIED)
Approved for use through 9/30/98, OMB 0651-0027
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

## CERTIFICATE UNDER 37 CFR 3.73(b) First Applicant: REMICK David Michael Serial No.: PCT/US2004/000020 Application Date: January 21, 2004 (21.01.04) US Nat'l Entry Date: Entitled: CRYSTALLINE NON-SOLVATED 1-(4-(2-PIPERIDINYLETHOXY)PHENOXY)-2-(4-METHANESULFONYLPHENYL)-6-HYDROXYNAPHTHALENE HYDROCHLORIDE ELI LILLY AND COMPANY, an Indiana Corporation (Type of Assignee, e.g. corporation, partnership, university, government agency, etc.) certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either: [x] An assignment from the inventor(s) of the patent application identified above. [ ] The assignment was recorded in the Patent and Trademark Office at Reel [x] The assignment is being submitted separately for recordation; a copy of this assignment is attached. OR B. [ ] A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below: 1. To: The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame\_\_\_\_\_, or for which a copy thereof is attached. 2. To: The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame\_\_\_\_\_, or for which a copy thereof is attached. 3. From: To: The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame\_\_\_\_\_, or for which a copy thereof is attached. [ ] Additional documents in the chain of title are listed on a supplemental sheet. [ ] Copies of assignments or other documents in the chain of title are attached. The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.